Thus, results of this investigation demonstrate that the combination of EWS shRNA plasmid transfection and TFL treatment can offer a novel therapeutic strategy for controlling the growth of human Ewing’s sarcoma. This evidence concerns the gene EWSR1 and Ewing sarcoma.